CSBIO(SZ:300255) Xin Lang Cai Jing·2026-01-12 07:48Group 1 - The core point of the news is that Changshan Pharmaceutical has experienced a decline in stock price, dropping 2.02% to 57.79 CNY per share, with a total market capitalization of 53.113 billion CNY and a cumulative drop of 9.33% over three consecutive days [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, specializes in the research, production, and sales of heparin series products, with revenue composition of 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other sources [1] Group 2 - From the perspective of major fund holdings, one fund under the Fuguo Fund has a significant position in Changshan Pharmaceutical, with the Fuguo Growth ETF (159571) reducing its holdings by 10,400 shares in the third quarter, now holding 14,500 shares, which represents 1.73% of the fund's net value [2] - The Fuguo Growth ETF (159571) has a current scale of 38.1675 million CNY, with a year-to-date return of 8.24% and a one-year return of 48.74% [2]